Psychometric Evaluation of the Functional Assessment of HIV Infection (FAHI) Questionnaire and Its Usefulness in Clinical Trials

Overview

Journal Qual Life Res

Specialties Pharmacology
Rehabilitation Medicine

Date 2010 May 29

PMID 20509050

Citations 9

Authors

Muriel Viala-Danten

Dominique Dubois

Helene Gilet

Silas Martin

Katrien Peeters

David Cella

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate psychometric properties of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) questionnaire, a 47-item disease-specific instrument evaluating Health-Related Quality of Life (HRQL) in human immunodeficiency virus (HIV)-infected patients.

Methods: Treatment-experienced HIV-infected patients from two clinical programmes (N = 565; N = 1,096) completed the FAHI at Baseline and after 24 weeks of treatment. Psychometric properties of the FAHI were assessed in both trial populations, including minimal important differences (MIDs) calculations. Links between HRQL assessed by FAHI Total score, and biological endpoints were explored by regression analysis and mean score comparisons.

Results: Cronbach's alphas ranged from 0.72 to 0.94. Most items met convergent and discriminant validity criteria. Better FAHI scores were seen for patients in earlier HIV stages. Responsiveness was demonstrated with changes in FAHI scores significantly linked to change in EQ-5D score. Depending on methods used, MIDs ranged from 3.2 to 14 for FAHI Total score. Small association was found between FAHI Total score and CD4 count and viral load (r-square < 3%). Mean changes in FAHI scores were not statistically related to viral response.

Conclusions: The FAHI demonstrated acceptable psychometric properties in two independent populations. HRQL assessment enabled detection of changes in patients' health status not revealed by traditional efficacy endpoints.

Citing Articles

HIV-Specific Reported Outcome Measures: Systematic Review of Psychometric Properties.

Wang Z, Zhu Y, Duan X, Kang H, Qu B JMIR Public Health Surveill. 2022; 8(12):e39015.

PMID: 36222289 PMC: 9782451. DOI: 10.2196/39015.

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals.

Anderson S, Murray M, Cella D, Grossberg R, Hagins D, Towner W Patient. 2021; 15(1):131-143.

PMID: 34180035 PMC: 8739158. DOI: 10.1007/s40271-021-00534-y.

Correlates of health-related quality of life among adults receiving combination antiretroviral therapy in coastal Kenya.

Nyongesa M, Mwangi P, Wanjala S, Mutua A, Koot H, Cuijpers P Health Qual Life Outcomes. 2020; 18(1):169.

PMID: 32503558 PMC: 7275333. DOI: 10.1186/s12955-020-01421-0.

Depressive symptoms, physical symptoms, and health-related quality of life among older adults with HIV.

Olson B, Vincent W, Meyer J, Kershaw T, Sikkema K, Heckman T Qual Life Res. 2019; 28(12):3313-3322.

PMID: 31446515 PMC: 6868331. DOI: 10.1007/s11136-019-02271-0.

A mixed methods approach to adapting and evaluating the functional assessment of HIV infection (FAHI), Swahili version, for use with low literacy populations.

Nyongesa M, Sigilai A, Hassan A, Thoya J, Odhiambo R, van de Vijver F PLoS One. 2017; 12(4):e0175021.

PMID: 28380073 PMC: 5381886. DOI: 10.1371/journal.pone.0175021.

References

Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm D . A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998; 12(7):F51-8. DOI: 10.1097/00002030-199807000-00003. View

Walters S, Brazier J . Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005; 14(6):1523-32. DOI: 10.1007/s11136-004-7713-0. View

Valdez Madruga J, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A . Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007; 370(9581):29-38. DOI: 10.1016/S0140-6736(07)61047-2. View

Bonomi A, Cella D, Hahn E, Bjordal K, Sperner-Unterweger B, Gangeri L . Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res. 1996; 5(3):309-20. DOI: 10.1007/BF00433915. View

Yost K, Sorensen M, Hahn E, Glendenning G, Gnanasakthy A, Cella D . Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument. Value Health. 2005; 8(2):117-27. DOI: 10.1111/j.1524-4733.2005.08202.x. View

Revicki D, Wu A, Murray M . Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Med Care. 1995; 33(4 Suppl):AS173-82. View

van Sighem A, van de Wiel M, Ghani A, Jambroes M, Reiss P, Gyssens I . Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS. 2003; 17(15):2227-36. DOI: 10.1097/00002030-200310170-00011. View

Guyatt G, Osoba D, Wu A, Wyrwich K, Norman G . Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002; 77(4):371-83. DOI: 10.4065/77.4.371. View

Weinfurt K, Willke R, Glick H, Freimuth W, Schulman K . Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. Med Care. 2001; 38(4):404-10. DOI: 10.1097/00005650-200004000-00007. View

10.

Walensky R, Paltiel A, Losina E, Mercincavage L, Schackman B, Sax P . The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006; 194(1):11-9. DOI: 10.1086/505147. View

11.

. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006; 4:79. PMC: 1629006. DOI: 10.1186/1477-7525-4-79. View

12.

Schag C, Ganz P, Kahn B, Petersen L . Assessing the needs and quality of life of patients with HIV infection: development of the HIV Overview of Problems-Evaluation System (HOPES). Qual Life Res. 1992; 1(6):397-413. DOI: 10.1007/BF00704434. View

13.

Dolan P . Modeling valuations for EuroQol health states. Med Care. 1997; 35(11):1095-108. DOI: 10.1097/00005650-199711000-00002. View

14.

Eremenco S, Cella D, Arnold B . A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof. 2005; 28(2):212-32. DOI: 10.1177/0163278705275342. View

15.

Gulick R . Current antiretroviral therapy: an overview. Qual Life Res. 1997; 6(6):471-4. DOI: 10.1023/a:1018447829842. View

16.

Agrawal L, Lu X, Jin Q, Alkhatib G . Anti-HIV therapy: Current and future directions. Curr Pharm Des. 2006; 12(16):2031-55. DOI: 10.2174/138161206777442100. View

17.

Leplege A, Rude N, Ecosse E, Ceinos R, Dohin E, Pouchot J . Measuring quality of life from the point of view of HIV-positive subjects: the HIV-QL31. Qual Life Res. 1997; 6(6):585-94. DOI: 10.1023/a:1018468301617. View

18.

Miller J, Carr A, Emery S, Law M, Mallal S, Baker D . HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003; 4(3):293-301. DOI: 10.1046/j.1468-1293.2003.00159.x. View

19.

Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View

20.

Rao D, Hahn E, Cella D, Hernandez L . The health related quality of life outcomes of English and Spanish speaking persons living with HIV/AIDS from the continental United States and Puerto Rico. AIDS Patient Care STDS. 2007; 21(5):339-46. DOI: 10.1089/apc.2006.0124. View